You need to be logged in to view this video

Strong Drug Launches Demonstrate Value of De-Risked Biotech Companies with Recently Approved Drugs

Released on Thursday, June 9, 2022•BIOTECH

Share
Facebook Twitter LinkedIn SMS

Among the recently completed Q1 earnings reports, there were a handful of successful biotechs with improving sales/earnings and higher forecasts from new product launches. In biotech, Bear market investors demand positive growth trends from new, approved drugs and avoid regulatory or clinical risk.

John McCamant

Medical Technology Stock Letter, Editor

John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.